Key Market Overview:
Rabies Diagnostics Market size was valued at USD 1,669.86 Million in 2022, registering a CAGR of 3.8% during the forecast period (2023-2030), and the market is projected to be worth USD 2,237.76 Million by 2030.
Human rabies can be diagnosed by various laboratory diagnostic tests such as fluorescent antibody tests, immunohistochemical tests, serology tests, and others. Further, dogs are the prime source of most human rabies deaths, contributing up to 99% of all rabies transmissions to humans.
The increasing incidence of human rabies infection is accelerating the demand for rabies diagnostics market. For instance, according to the World Health Organization (WHO), in 2023, India accounts for 36% of global deaths due to rabies. India also accounts for 65% of the deaths due to rabies in the South-East Asia region. Henceforth, the increase in the prevalence of rabies diseases is fostering the growth of the market.
Moreover, the growing adoption of cutting-edge point-of-care rabies diagnostic solutions worldwide due to rapid diagnosis of infectious diseases in non‐laboratory settings will create lucrative growth opportunities for the rabies diagnostics market.
Rabies Diagnostics Market Report Coverage:
|Report Attributes||Report Details|
|Market Size in 2030 (USD Million)||2,237.76 Million|
|By Test Type||Fluorescent Antibody Test, Immunohistochemical Test, Amplification Methods, Histologic Examination, Serology Tests, Mouse Inoculation Test|
|By Technology||ELISA, PCR, Chromatography Techniques, And Others|
|By End User||Hospitals, Diagnostic Centers, Cancer Palliative Care Clinics, And Others|
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey]
- North America [United States, Canada, Mexico]
- Middle East & Africa [GCC, North Africa, South Africa]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
|Key Players||Bio-Rad Laboratories, Merck KGaA, Aviva Systems Biology, Creative Diagnostics, MyBioSource, Abbexa Ltd, Norgen Biotek, EXPRESS BIOTECH INTERNATIONAL, INC|
The diagnosis of rabies is vital for accurate and timely diagnosis to initiate appropriate treatment. The high incidence of rabies particularly in countries such as India, China, and others is increasing due to the inadequate animal vaccination programs. For instance, according to the World Health Organization (WHO), The National Rabies Control Program reported 6,644 clinically suspected cases and deaths of human rabies between 2012 and 2022. In India, the sudden spike in the number of cases of rabies is a major public health concern. Thus, the increased incidence of human rabies infection worldwide is propelling the growth of the rabies diagnostic market.
People are affected by infectious animal diseases due to their close contact with livestock and other animals. However, animal disease surveillance and diagnosis in low- and middle-income is often challenging and there is limited access to the diagnostic test for rabies. Furthermore, inadequate access to diagnostic tests and costs associated with preventative treatment are some of the key factors restraining the growth of the rabies diagnostic market. For instance, in a 2021 study published by the National Institute of Health, in Vietnam suspected avian influenza samples take an average of 6–24 hours to reach a diagnostic laboratory, with total turnaround times from submission to result averaging 2.5 days. Henceforth, the lack of well-equipped laboratories is restraining the growth of the market.
The continuous advancement in diagnostic technologies offers opportunities for the rabies diagnostics market. Development for superior accurate, rapid, and cost-effective diagnostic tests can improve the efficiency and effectiveness of the rabies diagnostic market. This, in turn, leads to efficient disease management and control. For instance, in 2023, Bio-Rad Laboratories, Inc launched of CFX Opus Deepwell Dx Real-Time PCR System, a real-time PCR system listed with the U.S. Food and Drug Administration (FDA) for in vitro diagnostic (IVD) testing.
Henceforth, the recent developments in advanced diagnostic technology will create opportunities for the rabies diagnostic market in the forecast year.
Rabies Diagnostics Market Segmentation:
By Test Type:
The test type segment is classified into fluorescent antibody test, immunohistochemical test, amplification methods, histologic examination, serology tests, and mouse inoculation test. The fluorescent antibody test segment accounted for the highest market share and is expected to be the fastest-growing CAGR in the rabies diagnostic market. The fluorescent antibody test is equipped with various beneficial functioning such as rapid results, superior accuracy in testing, and others. As a result, the fluorescent antibody test is frequently utilized for the diagnosis of rabies. For instance, in 2022, Fluorescent Antibody Test (FAT) is recommended by World Health Organization (WHO) and in 95-99% of cases, gives reliable results on fresh specimens within a few hours. Thus, the international organizations recommendations for the use of fluorescent antibody tests in the diagnosis of rabies are favoring the market growth.
The technology segment is classified into ELISA, PCR, chromatography techniques, and others. In 2022, the ELISA segment accounted for the highest market share and CAGR in the rabies diagnostic market. The key benefits associated with the ELISA such as simple procedure, high specificity, and sensitivity ensure efficient results for complicated sample pre-treatment, and others. Thus, ELISA is utilized for the detection of rabies virus nucleocapsid antigens in brain tissue. For instance, in 2021, as per the Japan International Corporation Agency, Rapid test kits for rabies were launched in the Philippines recently to support early detection of rabies in high-risk areas. The ICT kits offer an innovative way to tackle rabies prevention and diagnosis in the Philippines. Hence, the recent technological innovations for ELISA will create a prominent growth opportunity for the market during the projected forecast period.
The end-use market is segmented into hospitals, diagnostic centers, cancer palliative care clinics, and others. In 2022, hospitals segment accounted for the highest market share in the rabies diagnostic market. In hospitals, the adoption of diagnostic tests such as fluorescent antibody test, immunohistochemical test, and amplification methods, among others are increasing to enable the treatment of rabies diseases. Also, hospitals are the first point of care for patients. For instance, as per the U.S. Department of Health & Human Services, in March 2020, approximately 90% of hospitalized where Most of the hospitalized patients had underlying conditions, some of which are recognized to be associated with severe COVID-19 disease, including chronic lung disease, cardiovascular disease, diabetes mellitus.
The diagnostic centers segment is expected to register the fastest-growing CAGR during the forecast period. This is due to the increasing prevalence of rabies.
By region, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. In 2022, North America accounted for the highest market in terms of revenue for rabies diagnostic market. The prime factors such as the growing number of rabies diagnostic tests, increased healthcare expenditures, and advanced healthcare infrastructure in the region and others are some of the vital aspects accelerating the adoption of rabies diagnostic in the North America region. For instance, in March 2023, as per the Centers for Disease Control and Prevention, about 5,000 animal rabies cases are reported in the US each year, with more than 90% of the cases occurring in wildlife. Furthermore, about 10% of animal rabies cases in the US occur in domestic animals such as dogs and cats. Henceforth, the increasing adoption of rabies diagnosis in the North America region is driving the market growth.
The Asia Pacific market accounted for the highest CAGR during the forecast period due to the growing involvement of many non-profit organizations to control the disease and increasing healthcare initiatives by governments to control the spread of rabies in this region.
Rabies Diagnostics Market Competitive Landscape:
The rabies diagnostic test market is highly competitive, with several large players and numerous small and medium-sized enterprises. These companies have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships. The key players in the market include –
• Bio-Rad Laboratories
• Merck KGaA
• Aviva Systems Biology
• Creative Diagnostics
• Abbexa Ltd
• Norgen Biotek
• EXPRESS BIOTECH INTERNATIONAL, INC
• In 2023, Bio-Rad Laboratories, Inc.in announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, a real-time PCR system listed with the U.S. Food and Drug Administration (FDA) for in vitro diagnostic (IVD) testing.